Corindus Vascular Robotics (NYSEAMERICAN:CVRS) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report issued on Tuesday, Zacks.com reports.

According to Zacks, “Corindus Vascular Robotics, Inc. is involved in designing, manufacturing and selling precision vascular robotic-assisted systems for interventional vascular procedures. The Company’s product includes CorPath 200 system a vascular robotic system which provide stent placement in percutaneous coronary intervention procedures. Corindus Vascular Robotics, Inc. is based in Waltham, Massachusetts. “

Shares of CVRS traded down $0.04 during mid-day trading on Tuesday, reaching $2.63. The company’s stock had a trading volume of 858,700 shares, compared to its average volume of 1,179,292. Corindus Vascular Robotics has a 12-month low of $0.70 and a 12-month high of $3.10.

Corindus Vascular Robotics (NYSEAMERICAN:CVRS) last released its quarterly earnings data on Tuesday, May 7th. The medical equipment provider reported ($0.05) EPS for the quarter, meeting analysts’ consensus estimates of ($0.05). The business had revenue of $3.04 million during the quarter, compared to analysts’ expectations of $2.90 million.

In other news, major shareholder Hudson Executive Capital Lp purchased 2,899,391 shares of the company’s stock in a transaction that occurred on Tuesday, March 12th. The shares were purchased at an average price of $1.38 per share, for a total transaction of $4,001,159.58. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Louis A. Cannon purchased 573,798 shares of the company’s stock in a transaction that occurred on Tuesday, March 12th. The shares were purchased at an average price of $1.38 per share, for a total transaction of $791,841.24. The disclosure for this purchase can be found here. Insiders have purchased a total of 3,483,189 shares of company stock worth $4,811,001 in the last 90 days.

A number of large investors have recently added to or reduced their stakes in CVRS. Jane Street Group LLC purchased a new position in Corindus Vascular Robotics during the 4th quarter worth approximately $36,000. HRT Financial LLC acquired a new stake in Corindus Vascular Robotics during the 4th quarter worth approximately $44,000. Canton Hathaway LLC acquired a new stake in Corindus Vascular Robotics during the 1st quarter worth approximately $63,000. Virtu Financial LLC acquired a new stake in Corindus Vascular Robotics during the 4th quarter worth approximately $64,000. Finally, Weiss Asset Management LP acquired a new stake in Corindus Vascular Robotics during the 1st quarter worth approximately $65,000.

Corindus Vascular Robotics Company Profile

Corindus Vascular Robotics, Inc designs, manufactures, and sells robotic-assisted systems for use in interventional vascular procedures in the United States and internationally. The company offers CorPath system, a medical device with robotic-assisted precision for coronary and peripheral interventional procedures.

Recommended Story: Conference Calls

Get a free copy of the Zacks research report on Corindus Vascular Robotics (CVRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Corindus Vascular Robotics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corindus Vascular Robotics and related companies with MarketBeat.com's FREE daily email newsletter.